Search Result

Results for "

Antagonism

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (3) Bacterial (1) CaMK (1) CCR (4) CXCR (1) Dopamine Receptor (11) Endogenous Metabolite (2) ERK (1) FXR (1) GHSR (1) Glucocorticoid Receptor (1) Histamine Receptor (2) iGluR (3) Isotope-Labeled Compounds (2) LPL Receptor (1) mAChR (1) Melanocortin Receptor (1) Neuropeptide Y Receptor (1) Nuclear Hormone Receptor 4A/NR4A (1) Opioid Receptor (9) Orphan Receptor (1) Oxytocin Receptor (1) P2X Receptor (1) P2Y Receptor (1) Parasite (2) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (1) PKA (1) PPAR (1) SARS-CoV (8) Sodium Channel (7) TRP Channel (1) Virus Protease (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (4) Endocrinology (6) Infection (7) Inflammation/Immunology (11) Metabolic Disease (7) Neurological Disease (24)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (3)

Bacterial (1)

CaMK (1)

CCR (4)

CXCR (1)

Dopamine Receptor (11)

Endogenous Metabolite (2)

ERK (1)

FXR (1)

GHSR (1)

Glucocorticoid Receptor (1)

Histamine Receptor (2)

iGluR (3)

Isotope-Labeled Compounds (2)

LPL Receptor (1)

mAChR (1)

Melanocortin Receptor (1)

Neuropeptide Y Receptor (1)

Nuclear Hormone Receptor 4A/NR4A (1)

Opioid Receptor (9)

Orphan Receptor (1)

Oxytocin Receptor (1)

P2X Receptor (1)

P2Y Receptor (1)

Parasite (2)

PD-1/PD-L1 (2)

Phosphodiesterase (PDE) (1)

PKA (1)

PPAR (1)

SARS-CoV (8)

Sodium Channel (7)

TRP Channel (1)

Virus Protease (1)

By Research Areas:

Cancer (12)

Cardiovascular Disease (4)

Endocrinology (6)

Infection (7)

Inflammation/Immunology (11)

Metabolic Disease (7)

Neurological Disease (24)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13290

KN-62 5+ Cited Publications	CaMK P2X Receptor	Metabolic Disease Cancer
KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a K_i of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X₇ receptors in HEK293 cells, with an IC₅₀ value of approximately 15 nM.

HY-50674

INCB3344 Maximum Cited Publications 22 Publications Verification	CCR	Inflammation/Immunology Endocrinology
INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

HY-50674A

INCB3344 R-isomer	CCR	Inflammation/Immunology
INCB3344 R-isomer is the R-isomer of INCB3344. INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity .

HY-77111

cis-INCB3344	Others	Inflammation/Immunology Endocrinology
cis-INCB3344 is the isomer of INCB3344 (HY-50674), and can be used as an experimental control. INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

HY-149387

D3R/MOR antagonist 2	Dopamine Receptor Opioid Receptor	Inflammation/Immunology
D3R/MOR antagonist 2 (Compound 121) is a D3R/MOR antagonist (K_i: 361 nM and 85.2 nM respectively). D3R/MOR antagonist 2 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism .

HY-149386

D3R/MOR antagonist 1	Dopamine Receptor Opioid Receptor	Inflammation/Immunology
D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (K_i: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism .

HY-19012

N-1518	Adrenergic Receptor	Cardiovascular Disease
N-1518 is an α and β adrenergic receptor blocker that has competitive antagonism against β1 and α1 receptors, but does not show selectivity for β1 receptors, but shows about 20-fold selectivity for α1 receptors. N-1518 has vasodilatory effects and can be used in the research field of hypertension treatment .

HY-120301

L-366682	Oxytocin Receptor	Endocrinology
L-366682, a cyclic hexapeptide, possesses antagonism of oxytocin .

HY-P5175

Muscarinic toxin 7	mAChR	Neurological Disease
Muscarinic toxin 7 is a peptide toxin with selective and noncompetitive antagonism at the muscarinic M1 receptor .

HY-159080

HgCht2-IN-1	Parasite	Infection
HgCht2-IN-1 (compound 1516b) is a HgCht2 inhibitor that successfully inhibits the antagonism of cyst nematodes against nitrogen-fixing rhizobia and phosphate-absorbing arbuscular mycorrhizal symbionts. HgCht2-IN-1 can be used in the study of cyst nematode antagonism against microbial symbionts .

HY-120188

CC618	PPAR	Others
CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors .

HY-124910

BU-E-75	Histamine Receptor Adrenergic Receptor	Cardiovascular Disease
BU-E-75 is a guanidine-type H₂ receptor agonist that exhibits antagonism at postsynaptic α-adrenoceptors, which can relax the noradrenaline-precontracted vessels .

HY-115844

LY-99335	Opioid Receptor Endogenous Metabolite	Neurological Disease
LY-99335 is an anesthetic antagonist with behavioral inhibitory activity. LY-99335 exhibits large dose separation at specific doses, indicating its potential in anesthetic antagonism .

HY-136880

Flufylline Sgd 195/78	5-HT Receptor	Cardiovascular Disease
Flufylline shows antihypertensive properties in spontaneously hypertensive rats and display antagonism towards 5-HT receptors in various animal models. Flufylline can be used for cardiovascular disease research .

HY-164128

AHL modulator-1	Others	Others
AHL modulator-1 (compound 12) is a modulator of N-acylated L-homoserine lactone (AHL), with the agonism and antagonism of 21% and 42% in cellulase activity and 5% and 32% in potato macerationa, respectively .

HY-W650803

Nemazoline A-57219	Adrenergic Receptor	Cardiovascular Disease
Nemazoline (A-57219) is selective α-adrenergic agent with α₁-agonist/α₂-antagonist activity, which is used as a nasal decongestant. Nemazoline produces decongestion by α₁-mediated contraction of capacitance vessels, but not compromises blood flow by virtue of α₂-antagonism. Nemazoline also blocks endogenous noradrenaline-mediated α ₂-constriction of the resistance vessels .

HY-163703

D4R antagonist-2	Dopamine Receptor	Neurological Disease
D4R antagonist-2 (compound 33) is a D4R antagonist. D4R antagonist-2 has a IC₅₀ value of 210 nM, and a Ki value of 59 nM for D4R. D4R antagonist-2 can be used in the Parkinson's disease research .

HY-142066

4′-Demethylnobiletin	PKA ERK iGluR	Neurological Disease
4′-Demethylnobiletin is a bioactive metabolite that activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment associated with NMDA receptor antagonism by stimulating ERK signaling .

HY-16039

AM095 5+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM095 is a selective LPA₁ receptor antagonist. The IC₅₀ for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA₁-transfected CHO cells is 0.025 and 0.023 μM, respectively.

HY-125839

OP-3633	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
OP-3633 is a potent and selective steroidal glucocorticoid receptor (GR) antagonist with an IC₅₀ of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism .

HY-N7740

Adenosine 2',5'-diphosphate sodium	P2Y Receptor Endogenous Metabolite	Others
Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet P2X1 receptors .

HY-113906A

(αR,8aS)-GSK1614343	GHSR	Metabolic Disease
(αR,8aS)-GSK1614343 is the isomer of GSK1614343 (HY-113906). GSK1614343 is the potent antagonist of growth hormone secretagogues type 1a (GHS1a) receptors .

HY-P0262A

Galantide TFA	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease
Galantide TFA is a reversible and non-specific galanin (GAL) receptor antagonist. Galantide TFA dose-dependently shows antagonism to galanin-induced K ⁺ conductance with an IC₅₀ value of 4 nM. Galantide TFA can be used for the research of neurological disease and hormone metabolism research .

HY-161896

Transcription factor-IN-1	Others	Neurological Disease
Transcription factor-IN-1 (Compound 4e) is an inhibitor for transcription factor. Transcription factor-IN-1 exhibits anticonvulsant activity by antagonism with pentylenetetrazole (PTZ) (ED₅₀ =34.5 mg/kg). Transcription factor-IN-1 exhibits antidepressant effects in rat models .

HY-101908

BMS CCR2 22	CCR	Inflammation/Immunology Endocrinology
BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC₅₀ of 5.1 nM) and potent functional antagonism (calcium flux IC₅₀ of 18 nM and chemotaxis IC₅₀ of 1 nM) .

HY-136299A

Sepimostat dimethanesulfonate FUT-187	iGluR	Neurological Disease
Sepimostat dimethanesulfonate (FUT-187) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat dimethanesulfonate inhibits the Ifenprodil binding with a K_i value of 27.7 µM .

HY-161273

TRPV1 antagonist 6	TRP Channel	Neurological Disease
TRPV1 antagonist 6 (compound 51) is a mode-selective antagonist for transient receptor potential vanilloid member 1 (TRPV1), which shows antagonism with IC₅₀ of 2.85 nM to capsaicin activation and 28.48 % inhibition against proton activation at a 3 µM concentration .

HY-117881

CJ-15208	Opioid Receptor	Neurological Disease
CJ-15208 is a potent and selective κ-opioid receptor antagonist with significant opioid activity. CJ-15208 exhibited strong analgesic effects in the warm water tail withdrawal test in mice and was mediated through multiple opioid receptors. The stereoisomers of CJ-15208 exhibited different opioid activity characteristics, for example, one stereoisomer exhibited κ-opioid receptor antagonism, while the other exhibited δ-opioid receptor antagonism. All stereoisomers of CJ-15208 had no significant effects on respiration. The stereoisomers of CJ-15208 did not lead to the development of drug tolerance, which makes it potential in the further development of safe opioid analgesics .

HY-136299

Sepimostat 1 Publications Verification FUT-187 free base	iGluR	Neurological Disease
Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a K_i value of 27.7?μM .

HY-119971

BIM5078	Nuclear Hormone Receptor 4A/NR4A	Metabolic Disease Cancer
BIM5078 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BIM5078 represses insulin promoter activity through HNF4α antagonism. BIM5078 can be used for the research of cancer and diabetes .

HY-W424730

HA-966 hydrochloride	Others	Others
HA-966 hydrochloride is a glycine site antagonist of the NMDA receptor, exhibiting non-competitive antagonism on NMDA responses. HA-966 hydrochloride effectively blocks the enhancement of NMDA responses by glycine in a competitive manner. HA-966 hydrochloride plays a significant role in mediating the antagonist action at the glycine modulatory site of the NMDA receptor.

HY-108469

BI-6015 3 Publications Verification	Orphan Receptor	Metabolic Disease Cancer
BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes .

HY-P10571

GPS1573	Melanocortin Receptor	Endocrinology
GPS1573 is a noncompetitive antagonist of melanocortin type 2 receptor (MC2R) that dose-dependently antagonizes ACTH-stimulated MC2R activity (IC₅₀=66 nM). GPS1573 can be used in the study of Cushing's disease due to its highly selective antagonism of MC2R .

HY-155706

MOR agonist-2	Opioid Receptor Dopamine Receptor	Inflammation/Immunology
MOR agonist-2 (compound 46) is a antagonist of D3R and agonist of MOR (K_i: 7.26 nM and 564 nM, respectively). MOR agonist-2 has the potential to produce analgesic effects through MOR partial agonism. MOR agonist-2 reduces opioid-misuse liability via D3R antagonism .

HY-13499

JNJ-41443532 CCR2 antagonist 5	CCR	Inflammation/Immunology
JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC₅₀=37 nM) and potent functional antagonism (chemotaxis IC₅₀=30 nM). JNJ-41443532 displays a K_i of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease .

HY-156734

D-4-77	SARS-CoV Virus Protease	Infection
D-4-77 is a potent inhibitor of SARS-CoV-2 Mpro with an IC₅₀ value of 0.95 μM. D-4-77 has antiviral active with an EC₅₀ value of 0.49 μM. D-4-77 suppresses SARS-CoV-2 Mpro -induced antagonism of the host NF-κB innate immune response .

HY-P1812

AUNP-12 3 Publications Verification NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .

HY-144608

Mu opioid receptor antagonist 3	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 3 (compound 26) is a potent and selective μ opioid receptor (MOR) antagonist with a K_i of 0.24 nM and an EC₅₀ of 0.54 nM. Mu opioid receptor antagonist 3 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 3 can be used for researching opioid use disorders (OUD) .

HY-148038

5-HT3 antagonist 5	5-HT Receptor	Neurological Disease
5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT₃ receptor antagonist. 5-HT3 antagonist 5 exerts antagonism on 5-HT₃ agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice .

HY-101725

Meclonazepam Ro 11-3128; Ro 11-3128/002	Parasite	Infection Neurological Disease
Meclonazepam (Ro 11-3128) is a benzodiazepine compound with anxiolytic effect . Meclonazepam is active against immature S. mansoni. Meclonazepam (30 μM) eliminates 100% of immature parasites. Meclonazepam has a anti-schistosomal effect .

HY-P1812A

AUNP-12 TFA 3 Publications Verification NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .

HY-144286

CXCR4 antagonist 3	CXCR	Infection
CXCR4 antagonist 3 (compound 12a) is a potent antagonist of CXCR4 with an IC₅₀ of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus .

HY-121037

Eggmanone EGM1	Phosphodiesterase (PDE)	Cancer
Eggmanone (EGM1) is a potent and selective phosphodiesterase 4 (PDE4) antagonist with an IC₅₀ of 72 nM for PDE4D3. Eggmanone shows approximately 40- to 50-fold selective for PDE4D3 over other PDEs. Eggmanone exerts its Hh-inhibitory effects through selective antagonism of PDE4, leading to protein kinase A activation and subsequent Hh blockade .

HY-151481

FXR antagonist 1	FXR	Metabolic Disease
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC₅₀=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .

HY-B1901

Eperisone hydrochloride (±)-Eperisone hydrochloride	Others	Neurological Disease
Eperisone Hydrochloride ((±)-Eperisone hydrochloride) is an orally active antispastic agent with a vasodilator effect, used for the research of muscle stiffness and pain. Eperisone Hydrochloride is a potent and selectively P2X7 receptor antagonist, also shows antagonism for human P2X3. Eperisone Hydrochloride works by relaxing both skeletal muscles and vascularsmooth muscles, demonstrating a variety of effects such as reduction ofmyotonia, improvement of circulationand and suppression of the pain reflex .

HY-144609

Mu opioid receptor antagonist 4	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 4 (compound 31) is a potent and selective μ opioid receptor (MOR) antagonist with a K_i of 0.38 nM and an EC₅₀ of 1.07 nM. Mu opioid receptor antagonist 4 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 4 Mu opioid receptor antagonist 4 can be used for researching opioid use disorders (OUD) .

HY-144607

Mu opioid receptor antagonist 2	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant μ opioid receptor (MOR) antagonist with a K_i of 0.37 nM and an EC₅₀ of 0.44 nM. Mu opioid receptor antagonist 2 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Mu opioid receptor antagonist 2 can be used for researching opioid use disorders (OUD) .

HY-107564

Impentamine dihydrobromide VUF 4702 dihydrobromide	Histamine Receptor	Inflammation/Immunology
Impentamine dihydrobromide (VUF 4702 dihydrobromide) is a histamine H3 receptor antagonist with potential antihistamine activity. Impentamine dihydrobromide shows the strongest selective H3 antagonism among a series of 4(5)-(ω-aminoalkyl)-1H-imidazole compounds. The pA2 value of impentamine dihydrobromide is 8.4, showing its high efficacy in guinea pig jejunum. Impentamine dihydrobromide has a specific antagonistic binding site with the H3 receptor .

HY-A0081

Fluphenazine dihydrochloride 1 Publications Verification	Dopamine Receptor SARS-CoV Sodium Channel	Neurological Disease Cancer
Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

HY-119980

Fluphenazine	Sodium Channel Dopamine Receptor SARS-CoV	Infection Neurological Disease Cancer
Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

Cat. No.	Product Name	Target	Research Area

HY-P0262A

Galantide TFA	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease
Galantide TFA is a reversible and non-specific galanin (GAL) receptor antagonist. Galantide TFA dose-dependently shows antagonism to galanin-induced K ⁺ conductance with an IC₅₀ value of 4 nM. Galantide TFA can be used for the research of neurological disease and hormone metabolism research .

HY-P1812

AUNP-12 3 Publications Verification NP-12	PD-1/PD-L1	Cancer
AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .

HY-P1812A

AUNP-12 TFA 3 Publications Verification NP-12 TFA	PD-1/PD-L1	Cancer
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .

HY-120301

L-366682	Oxytocin Receptor	Endocrinology
L-366682, a cyclic hexapeptide, possesses antagonism of oxytocin .

HY-P5175

Muscarinic toxin 7	mAChR	Neurological Disease
Muscarinic toxin 7 is a peptide toxin with selective and noncompetitive antagonism at the muscarinic M1 receptor .

HY-P10571

GPS1573	Melanocortin Receptor	Endocrinology
GPS1573 is a noncompetitive antagonist of melanocortin type 2 receptor (MC2R) that dose-dependently antagonizes ACTH-stimulated MC2R activity (IC₅₀=66 nM). GPS1573 can be used in the study of Cushing's disease due to its highly selective antagonism of MC2R .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7740

Adenosine 2',5'-diphosphate sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	P2Y Receptor Endogenous Metabolite
Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet P2X1 receptors .

Cat. No.	Product Name	Chemical Structure

HY-119980S

Fluphenazine-d8

Fluphenazine-d₈ is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

HY-119980BS

Fluphenazine-d6 hydrochloride

Fluphenazine-d₆ (hydrochloride) is deuterium labeled Fluphenazine (hydrochloride). Fluphenazine hydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine hydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine hydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine hydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine hydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks